Patents matching “formulation”

US 11000588

Etanercept formulations stabilized with sodium chloride

Coherus BioSciences, Inc. · Granted May 11, 2021 · Expires May 6, 2041

US 11000517

Dosage and formulation

Almirall, S.A. · Granted May 11, 2021 · Expires May 6, 2041

US 10987399

Stable formulations for parenteral injection of peptide drugs

XERIS PHARMACEUTICALS, INC. · Granted Apr 27, 2021 · Expires Apr 22, 2041

US 10960044

Powder formulation having hypoglycemic and hypolipidemic functions and method for preparing the same

INFINITUS (CHINA) COMPANY LTD. · Granted Mar 30, 2021 · Expires Mar 25, 2041

US 10954259

Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

Compass Pathfinder Limited · Granted Mar 23, 2021 · Expires Mar 18, 2041

US 10953018

Emulsion formulations of aprepitant

Heron Therapeutics, Inc. · Granted Mar 23, 2021 · Expires Mar 18, 2041

US 10947257

Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

Compass Pathfinder Limited · Granted Mar 16, 2021 · Expires Mar 11, 2041

US 10933042

Intravenous baclofen formulations and treatment methods

Regents of the University of Minnesota · Granted Mar 2, 2021 · Expires Feb 25, 2041

US 10913709

STAT3 inhibitor formulation

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 9, 2021 · Expires Feb 4, 2041

US 10912783

Formulations for solubilizing hormones

Compass Therapeutics LLC · Granted Feb 9, 2021 · Expires Feb 4, 2041

US 10912751

Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease

Esperion Therapeutics, Inc. · Granted Feb 9, 2021 · Expires Feb 4, 2041

US 10912741

Prevention of liver cancer with safranal-based formulations

UNITED ARAB EMIRATES UNIVERSITY · Granted Feb 9, 2021 · Expires Feb 4, 2041

US 10912834

Topical formulations based on ionic species for skin treatment

The Regents of the University of California · Granted Feb 9, 2021 · Expires Feb 4, 2041

US 10881104

Arthropod control composition, formulation, and method

TYRATECH, INC. · Granted Jan 5, 2021 · Expires Dec 31, 2040

US 10864175

Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

TONIX PHARMA LIMITED · Granted Dec 15, 2020 · Expires Dec 10, 2040

US 10864222

Beta-lactamase inhibitors, formulations, and uses thereof

The Regents of the University of California · Granted Dec 15, 2020 · Expires Dec 10, 2040

US 10864176

Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

TONIX PHARMA LIMITED · Granted Dec 15, 2020 · Expires Dec 10, 2040

US 10865400

PH20 polypeptide variants, formulations and uses thereof

HALOZYME, INC. · Granted Dec 15, 2020 · Expires Dec 10, 2040

US 10857231

Formulations of VEG antagonist fusion proteins and method of manufacturing them

REGENERON PHARMACEUTICALS, INC. · Granted Dec 8, 2020 · Expires Dec 3, 2040

US 10849891

Formulations of pimavanserin

ACADIA Pharmaceuticals Inc. · Granted Dec 1, 2020 · Expires Nov 26, 2040

US 10835517

Methods for treating ocular demodex using isoxazoline parasiticide formulations

Tarsus Pharmaceuticals, Inc. · Granted Nov 17, 2020 · Expires Nov 12, 2040

US 10835505

Oral pharmaceutical formulation for weight loss, diabetes and related disorders

Aardvark Therapeutics, Inc. · Granted Nov 17, 2020 · Expires Nov 12, 2040

US 10835597

Compositions and methods for stabilizing flaviviruses with improved formulations

Takeda Vaccines, Inc. · Granted Nov 17, 2020 · Expires Nov 12, 2040

US 10828265

Formulations of propranolol and analogs as an amorphous melt or ionic liquid for transdermal drug delivery

The Regents of the University of California · Granted Nov 10, 2020 · Expires Nov 5, 2040